Abbott Labs sales boosted by double-digit medical devices growth
The CEO at the Illinois-based company with operations in Minnesota expects earning to return to a pre-pandemic profit model ...
GlobalData on MSN8d
Abbott starts new trial to assess early use benefit of HeartMate 3
Abbott has launched a “first-of-its-kind” trial to identify advanced heart failure patients who could potentially benefit ...
Crain's Chicago Business17d
Abbott Labs board OKs $7 billion stock buyback program
Medical device giant Abbott Laboratories is launching a $7 billion stock buyback program. The repurchase of common shares was ...
What Drove Abbott's Q3?
Abbott (NYSE: ABT) recently reported its Q3 results, with revenues and earnings slightly above our expectations.
MassDevice9d
Abbott kicks off new trial aiming to improve heart failure outcomes with CardioMEMS, HeartMate 3
Abbott (NYSE:ABT) announced today that it launched a new clinical trial to help heart failure patients with advanced therapy ...
Abbott bumps up profit forecast on strong medical device sales
Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...
drugdeliverybusiness3d
FDA approves Abbott CGMs for use during medical imaging
Abbott announced today that the FDA said users can wear the FreeStyle Libre 2 and 3 CGMs during common imaging procedures.
Abbott Labs beats Q3 sales and earnings expectations, raises full-year outlook
Abbott Laboratories on Wednesday reported better-than-expected third-quarter earnings and sales, boosted by strength in the ...
Will glucose monitors become the next wellness accessory? Abbott Laboratories moves beyond diabetes with new device
A new device from Abbott Laboratories, called Lingo, is geared toward people who don’t have diabetes but want to see how food ...
Abbott Laboratories: Promising Growth, Yet Fully Valued; A Wait-And-Watch Stock
Abbott Laboratories, a healthcare giant with diverse divisions, is normalizing post-pandemic as its medical devices drive ...
Benzinga.com17d
Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast
Organic sales growth for the underlying base business was 8.2%, led by double-digit growth in Medical Devices. Abbott’s ...
Reuters17d
Abbott bumps up profit forecast on strong medical device sales
The company's medical devices unit generated $4.75 billion in sales for the third quarter, above analysts' average estimate of $4.68 billion, according to data compiled by LSEG. Overall ...